COSM Jumps 34.8% as EPS Revision Screener Flags Strongest Movers
Cosmos Health (COSM) led gainers with a 34.8% rally to $0.31 after its next-year EPS growth estimate was revised up 14.8 percentage points to 146.7% on October 26. Genmab (GMAB) rose 30.3% to $57.06 following positive Phase 3 cancer trial results and a J.P. Morgan upgrade, while Soluna (SLNH) gained 26.4% to $0.67 on its Applied Digital joint venture. XTI Aerospace (XTIA) and Insmed (INSM) added 23.5% and 20.6%, respectively, as earnings-estimate revisions preceded price confirmation across the group.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| COSM | Healthcare | 2026-10-26 | +14.8pp | +34.8% |
| GMAB | Healthcare | 2026-10-23 | N/A | +30.3% |
| SLNH | Financial | 2026-10-22 | N/A | +26.4% |
| XTIA | Industrials | 2026-10-22 | N/A | +23.5% |
| INSM | Healthcare | 2026-10-26 | +1.1pp | +20.6% |
Why did COSM stock jump in October 2026?
COSM jumped 34.8% (from $0.23 to $0.31) after its next-year EPS growth estimate was revised up to 146.7% on October 26, 2026.
The micro-cap healthcare name was flagged by our revision screener four days before the price move, with no company-specific news in the window. The gain reflects the market repricing a thin float against a materially improved forward earnings trajectory. With no fresh catalysts, the move appears technical and momentum-driven, reinforcing how early estimate revisions can precede price discovery in small-cap healthcare.
COSM EPS revision history → · Screener snapshot from 2026-10-26 →
FAQ: COSM
Why did COSM stock jump?
COSM jumped 34.8% to $0.31 after its next-year EPS growth estimate was revised upward by 14.8 percentage points to 146.7% on October 26, 2026.
What is COSM's EPS growth estimate?
Cosmos Health's next-year EPS growth estimate now stands at 146.7%, up from 131.8% before the revision.
Is COSM a buy after the rally?
The 34.8% move came without company-specific news, suggesting a technical repricing of the revised 146.7% EPS growth estimate; investors should weigh the micro-cap liquidity risk.
Why did GMAB stock jump in October 2026?
GMAB jumped 30.3% (from $43.79 to $57.06) after its next-year EPS growth estimate of 46.3% was reinforced by a J.P.
Morgan upgrade on October 27 and positive Phase 3 cancer trial data on October 28. J.P. Morgan raised its price target to DKr3,500 from DKr2,050 and lifted petosemtamab peak sales to $5 billion from $2.5 billion ahead of the readout. The Phase 3 LiGeR-HN1 trial then met both primary endpoints, reducing the risk of death by 50% versus pembrolizumab alone. The market confirmed the earnings-revision signal with two catalysts that materially de-risked the forward EPS trajectory.
GMAB EPS revision history → · Screener snapshot from 2026-10-23 →
FAQ: GMAB
Why did GMAB stock jump?
GMAB jumped 30.3% to $57.06 after a J.P. Morgan upgrade on October 27 and positive Phase 3 cancer trial results on October 28 reinforced its 46.3% next-year EPS growth estimate.
What caused Genmab's surge?
Genmab surged after its petosemtamab combination reduced the risk of death by 50% in the LiGeR-HN1 head and neck cancer trial, with J.P. Morgan raising its price target to DKr3,500 ahead of the data.
Is GMAB a buy after the rally?
The stock's 30.3% gain reflects a de-risked pipeline with petosemtamab peak sales now modeled at $5 billion and a 46.3% next-year EPS growth estimate, though shares are up sharply from the $43.79 detection price.
Why did SLNH stock jump in October 2026?
SLNH jumped 26.4% (from $0.53 to $0.67) after its next-year EPS growth estimate of 33.3% was carried forward by the October 22 announcement of an Applied Digital joint venture for a 50 MW AI data center at Project Dorothy 3.
Rosenblatt reiterated its Buy rating that same day, though it halved its price target to $2 from $4, still implying roughly 200% upside from the detection price. Applied Digital took a 51% controlling stake and supplied financing and the tenant, while Soluna retained 49% and contributed land and power assets. The structure lowers funding risk and supports the 33.3% forward EPS estimate that the screener flagged.
SLNH EPS revision history → · Screener snapshot from 2026-10-22 →
FAQ: SLNH
Why did SLNH stock jump?
SLNH jumped 26.4% to $0.67 after forming a joint venture with Applied Digital to develop a 50 MW AI data center at Project Dorothy 3, reinforcing its 33.3% next-year EPS growth estimate.
What is SLNH's EPS growth estimate?
Soluna Holdings has a next-year EPS growth estimate of 33.3%, which was flagged by our screener on October 22, 2026.
Is SLNH a buy after the rally?
Rosenblatt reiterated a Buy rating with a $2 target on October 22, implying substantial upside from $0.67, though the analyst noted the JV is less profitable than initially modeled.
Why did XTIA stock jump in October 2026?
XTIA jumped 23.5% (from $0.85 to $1.05) after its next-year EPS growth estimate of 74.6% was supported by preliminary third-quarter revenue of $35.3 million reported on October 22, in line with its 2026 outlook of $125 million to $130 million.
The company also announced a non-binding agreement on October 29 to restructure $4.5 million of defaulted seller notes, extending maturities and providing financial flexibility. Revenue grew roughly 9% sequentially on enterprise drone demand across public safety, government, energy, and agriculture. The combination of stable top-line performance and reduced near-term liquidity risk reinforced the forward earnings trajectory the screener detected.
XTIA EPS revision history → · Screener snapshot from 2026-10-22 →
FAQ: XTIA
Why did XTIA stock jump?
XTIA jumped 23.5% to $1.05 after preliminary Q3 revenue of $35.3 million aligned with its 2026 outlook and the company reached an agreement to restructure $4.5 million of defaulted promissory notes.
What is XTIA's EPS growth estimate?
XTI Aerospace has a next-year EPS growth estimate of 74.6%, which was flagged by our screener on October 22, 2026.
What caused XTI Aerospace's surge?
XTI Aerospace surged after reporting Q3 revenue of $35.3 million, up about 9% sequentially, and announcing a restructuring of $4.5 million in defaulted seller notes to extend maturities.
Why did INSM stock jump in October 2026?
INSM jumped 20.6% (from $93.33 to $112.58) after its next-year EPS growth estimate was revised up 1.1 percentage points to 151.8% on October 26, ahead of third-quarter results on October 29.
The company reported revenue of $524.4 million, beating the $501.3 million consensus and growing 268.4% year over year, driven by BRINSUPRI sales of $400.1 million. Insmed also raised its 2026 BRINSUPRI revenue guidance to $1.35 billion to $1.4 billion and launched the drug in Japan. The revenue beat and guidance raise confirmed the forward earnings trajectory that the revision screener had flagged three days earlier.
INSM EPS revision history → · Screener snapshot from 2026-10-26 →
FAQ: INSM
Why did INSM stock jump?
INSM jumped 20.6% to $112.58 after Q3 revenue of $524.4 million beat the $501.3 million consensus and the company raised its 2026 BRINSUPRI revenue guidance to $1.35 billion to $1.4 billion.
What is INSM's EPS growth estimate?
Insmed's next-year EPS growth estimate is 151.8%, revised up from 150.7% on October 26, 2026.
Is INSM a buy after the rally?
The 20.6% gain followed a revenue beat and raised BRINSUPRI guidance, though the quarter also included a wider-than-expected loss of $0.46 per share versus the $0.34 consensus estimate.
The group's gains were led by healthcare names where estimate revisions preceded clear catalysts, signaling that investors are rewarding forward earnings visibility in biotech and micro-cap healthcare. The common thread is that early EPS revisions, even without immediate news, can precede material price discovery when subsequent catalysts confirm the trajectory.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →